Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
333.35 | 572 Cr | 123.74 | 24.49 | 0.00 | 19.79 | 23.50 | 10.61 | ||
841.00 | 483 Cr | 21.39 | 1.23 | 0.59 | -0.38 | 0.75 | 4.35 | ||
1055.20 | 466 Cr | 14.18 | 2.36 | 1.96 | 17.63 | 23.20 | 14.53 | ||
367.00 | 449 Cr | 66.76 | 5.37 | 0.00 | 5.14 | 6.71 | 7.66 | ||
1450.00 | 438 Cr | 28.73 | 2.05 | 0.10 | 8.11 | 9.76 | 3.36 | ||
277.45 | 432 Cr | 35.58 | 3.57 | 0.00 | 10.04 | 16.02 | 8.12 | ||
287.00 | 387 Cr | 38.57 | 1.41 | 0.35 | 3.50 | 4.79 | 2.70 | ||
| Median: 7 Co. | — | 367.00 | 449 Cr | 35.58 | 2.36 | 0.10 | 8.11 | 9.76 | 7.66 |
Jenburkt Pharmaceuticals Ltd is a company engaged in the manufacturing and marketing of pharmaceutical formulations and healthcare products both in India and internationally.
The company operates a manufacturing plant in Gujarat that complies with WHO guidelines, demonstrating its commitment to quality and global standards.
Jenburkt has a vast distribution network of over 1,000 stockists, extending its reach to more than 400,000 pharmacies globally.
In recent years, the company diversified into the OTC market with the launch of its Jenburkt Wellness division, introducing products like Zixa Strong and Nervijen D3.
Pharmaceuticals & Biotechnology
Pharmaceuticals
466 Cr
Low Risk
14.2
37.7
1.1
2.4
1,321.00
944.00
Sales CAGR
Profit CAGR
ROE
ROCE
Jenburkt Pharmaceuticals Ltd (JENBURPH) is currently trading at 1,037.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Jenburkt Pharmaceuticals Ltd is a company engaged in the manufacturing and marketing of pharmaceutical formulations and healthcare products both in India and internationally. The company operates a manufacturing plant in Gujarat that complies with WHO guidelines, demonstrating its commitment to quality and global standards. Jenburkt has a vast distribution network of over 1,000 stockists, extending its reach to more than 400,000 pharmacies globally. In recent years, the company diversified into the OTC market with the launch of its Jenburkt Wellness division, introducing products like Zixa Strong and Nervijen D3.
Over the past 52 weeks, Jenburkt Pharmaceuticals Ltd has traded between a low of ₹944.00 and a high of ₹1,321.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Jenburkt Pharmaceuticals Ltd has a market capitalization of approximately 465.69. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Jenburkt Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 14.18 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 465.69 Cr, Jenburkt Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Jenburkt Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Jenburkt Pharmaceuticals Ltd is 14.18. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Shareholders approved a final dividend of ₹20.70 per equity share for FY26, described by the company as 207% on the ₹10 face value.
The 41st AGM is scheduled for Friday, September 4, 2026, at 3:30 p.m. IST, and will be held via VC/OAVM.
Bearish
3
Neutral
8
Bullish
3
Bearish
35
Neutral
8
Bullish
3
Bearish
32
Neutral
0
Bullish
0
Bearish
3
Neutral
8
Bullish
3
Bearish
3
Neutral
8
Bullish
3
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Change in Directors/KMP
Jenburkt Pharmaceuticals Ltd: Shareholders at the 41st AGM on 2026-09-04 approved re-appointment of Shri Dilip H. Bhuta as Whole Time Director & CFO for five years from 2027-04-01 to 2032-03-31; remuneration fixed for 2027-04-01 to 2030-03-31.
Regulatory/Compliance Filing
Jenburkt Pharmaceuticals filed consolidated voting results and the Scrutinizer's report for the 41st AGM held on 2026-09-04; all resolutions were passed and a dividend of ₹20.70 (207%) per share for FY2025-26 was declared.
AGM/EGM Notice
Jenburkt Pharmaceuticals Ltd held its 41st AGM on 2026-09-04 via VC; adopted FY2025-26 financials, declared dividend of ₹20.70 (207%) per share, re-appointed director/CFO and approved cost auditor remuneration.
Change in Directors/KMP
Jenburkt Pharmaceuticals Ltd elevated Prem Ashish Bhuta from Management Associate to Associate Vice President (AVP) - Strategic Initiatives, effective 2026-09-04; he is related to promoter Ashish U. Bhuta.
